Paladin acquires Pennsaid in Dimethaid Research deal

Paladin Labs has acquired Dimethaid Health Care, which owns the Canadian license for Pennsaid, a lotion approved by Health Canada for the treatment of symptoms of knee osteoarthritis. "Pennsaid offers a valuable treatment option to those suffering from osteoarthritis," said Jonathan Ross Goodman, president and CEO of Paladin Labs. "This is evidenced by the fact that for the first 6 months of 2005, Pennsaid sales increased by 40% versus last year. We expect that Pennsaid will be an $8-9 million brand in Canada by the end of 2005."

- read this press release for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.